



Minutes of Annual General Meeting 2025 (No. 47)
Aikchol Hospital Public Company Limited

Date and Venue

The meeting was held on Friday, April 18, 2025 at 10.00 a.m. at the Conference Room 1 on 3rd Floor of Aikchol 2 Hospital, No.31/2 Moo 2, Angsila Road, Samed Sub-district, Muang Chonburi province.

Directors in attendance At meeting room 1, 3rd floor, Aikchol Hospital

- | | | | |
|----|-----------------------|--------------------|---|
| 1) | Mr. Apirag | Vanich | Chairman |
| 2) | Asst.Prof.Krisda | Banchuin | Independent Director,
Chairman of the Audit Committee,
Chairman of the Nomination and Remunerati
Committee |
| 3) | Ms. Kanchana | Vanich | Director |
| 4) | Ms. Oranuj | Vanich | Director |
| 5) | Mrs. Thitawat | Pothanant | Independent Director,
Member of Audit Committee,
Member of the Nomination and Remuneratio
Committee |
| 6) | Assoc.Prof.Dr.Sarayut | Rueangsuwan, Ph.D. | Director, Member of the Nomination and
Remuneration Committee |
| 7) | Assoc.Prof.Pongsak | Yuktanandana, M.D. | Independent, Member of Audit Committee |

The proportion of directors attending the meeting was 87.5% of all directors.

Directors who did not attend the meeting At meeting room 1, 3rd floor, Aikchol Hospital

- | | | | |
|----|-----------|-------------|--|
| 1) | Mr. Kudun | Sukhumanada | Independent, Member of Audit Committee |
|----|-----------|-------------|--|

Executives in attendance At meeting room 1, 3rd floor, Aikchol Hospital

- | | | | |
|----|-------------------|----------------------------|---|
| 1) | Mr. Jakapan | Bhongsatiern | Chief Executive Officer |
| 2) | Mr. Siriphot | Manoch | Assistant Chairman of the Executive Officer,
Corporate Strategy Division |
| 3) | Mr. Nopparuj | Potcharakotchanun, M.D. | Hospital Director (Aikchol 1 Hospital) |
| 4) | Mr. Krittipat | Piriyakorncharoenkit, M.D. | Hospital Director (Aikchol 2 Hospital) |
| 5) | Mrs. Pariyanath | Chalermchuang | Chief Accounting and Finance Officer |
| 6) | Mr. Kitti | Pojpeinlert | Chief Marketing Officer |
| 7) | Mr. Sidthiphot | Manoch | Deputy Director of Accounting and Finance |
| 8) | Ms. Thanatchaporn | Sukha | Financial & Accounting Manager |
| 9) | Mrs. Wilailux | Srisuwan | Company Secretary |



Others in attendance

- | | | | |
|----|----------------|----------------|--|
| 1) | Ms. Thitinan | Luengpuangkaew | Legal Advisor from ILCT Co.,Ltd. |
| 2) | Ms. Suchaya | Chutikomol | Legal Advisor from ILCT Co.,Ltd. |
| 3) | Ms. Roongnapha | Saengchan | Representative of Auditor from Dharmniti Auditing Co.,Ltd. |
| 4) | Ms. Praneetsin | Foythong | Representative of Auditor from Dharmniti Auditing Co.,Ltd. |
| 5) | Ms. Potjanarat | Siripipat | Representative of Auditor from Dharmniti Auditing Co.,Ltd. |

Preliminary Proceedings

Mr. Apirak Vanich, Chairman of the Company, presided over the meeting (“the Chairman”). The Chairman invited Ms. Wilailak Srisuwan, Company Secretary, to assist in conducting the meeting on his behalf.

Ms. Wilailux Srisuwan Company Secretary Inform the meeting that, the Company had a total of 149,909,264 ordinary shares outstanding 10 persons representing 26,313,481 ordinary shares and 20 proxies representing 50,246,616 ordinary shares, representing a total of 30 shareholders and proxies, holding a total of 76,560,097 shares, representing 51.0710 percent of the total number of shares. Thus constituted a quorum under the Public Limited Companies Act B.E. 2535, Section 103 and Article 36 of the Company's Articles of Association In shareholders' meeting, there must not be less than twenty-five shareholders and proxies (if any) attending the meeting, or not less than half of the total number of shareholders and must have shares in aggregate not less than one-third of the total number of shares sold. Hence, a quorum was constituted.

The Chairman hereby declared of the 47th Annual General Meeting of 2025 and introduced the Company's directors, executives, other in attendees, who were representatives of the legal advisor, auditors, and assigned Ms. Wilailux Srisuwan, Company Secretary, to explain the voting procedures.

The Company Secretary informed the meeting that the Company would like to clarify the procedures for inquiries, voting, and vote counting as follows:

1. The voting method in the Company's shareholders' meeting, each agenda was as follows;

- (1) Shareholders or proxies have votes equal to the number of shares held. By using voting, disapproving shareholders or abstain from voting, raise your hand for the staff to collect the ballot.

- (2) Shareholder who submits a proxy form B to allow others to attend the meeting or assign it to directors or independent directors to vote. Also requiring proxies to vote according to the wishes of the shareholders or proxies. The company will vote according to the wishes of the shareholders or proxies.

Custodians appointed by foreign investors to hold and safeguard their shares may vote with all their voting rights or divide them up into votes of approval, disapproval, or abstention for each agenda item, but the total votes cast on each item may not exceed their voting rights.

2. Regarding the minutes of the 46th Annual General Meeting held on April 23, 2024, the Company has already disclosed these documents through both the Company's website and through the channel of the



Stock Exchange of Thailand within the prescribed timeline. This allowed all shareholders to review and propose amendments to the minutes, with no corrections being submitted. For reference, the minutes of the 46th Meeting have been attached to the convening notice of this 47th Annual General Meeting as Enclosure 1.

3. The Company allows shareholders or proxy holders to ask questions after each agenda presentation by raising their hands to indicate their intention to inquire. They must state their full name and declare to the meeting whether they are a shareholder or a proxy holder. Once all questions have been fully addressed, the Company Secretary will announce the opening of voting for each agenda item, with a 1-minute voting period per item. Voting will be closed once the allotted time has elapsed.

Agenda 1 is for acknowledgment, and thus there is no vote casting

Agenda 4 which is the appointment to replace those retiring directors by rotation, shareholders to vote individually.

Agenda 5 appointment of new directors and authorized signatories.

After the Company Secretary had clarified the procedures for each agenda item, the Chairman proceeded with the meeting in accordance with the agenda distributed to shareholders with the meeting notice, as follows:

Agenda 1 To acknowledge the report of the Board of Directors regarding business operations and the report 56-1 One Report for the year 2024

The Chairman informed the meeting that this agenda was to acknowledge the report of the Board of Directors regarding business operations and the report 56-1 One Report for the year 2024. Details appear in Enclosure 2 56-1 One Report 2024, which sent to all shareholders together with notice of the annual general meeting. The Chairman announced to the meeting that Agenda Item 1 pertains to the consideration and acknowledgment of

The Chairman assigned the Management team to report, Dr. Jakapan Bhongsatiern, M.D. to report on corporate governance in 2024, Dr. Nopparuj Potcharakotchanun, M.D. to report on the performance of Aikchol 1 Hospital, Dr. Krittipat Piriyakorncharoenkit, M.D. to report on Aikchol 2 Hospital and Ms. Pariyanat Chalermchuang to report on the overall financial and accounting performance of the company.

Dr. Jakapan Bhongsatiern, M.D. presented key performance results in corporate governance for the year 2024. The Company has updated its corporate governance policy to align with the current guidelines and has already published the revised policy on the Company's website. Regarding issues of conflicts of interest, insider trading, fraud, corruption, and complaints, the Company has not encountered any such cases in the past year or the preceding three years. Although the Company has not joined the Thai Private Sector Collective Action Coalition Against Corruption (CAC), it has established and implemented an anti-corruption policy and manual, which has been published on the Company's website.

Dr. Nopparuj Potcharakotchanun, M.D. Presenting the performance of Aikchol Hospital

In 2024, Aikchol Hospital aims to expand four centers of excellence: (1) Heart Disease Center, (2) Diabetes Center, (3) Beauty Center, and (4) Gastrointestinal Disease Center.



Heart Center provides comprehensive services for heart disease care, including treatment, rehabilitation, and prevention, using advanced technologies such as Echocardiogram and Cath Lab. The center also offers Cardiac Ablation for patients with arrhythmia. In 2024, the center expanded its services to include the treatment of congenital heart disease by performing ASD/VSD Closure.

DM Clinic provides screening and care for diabetic patients and those at risk through health check-ups and various activities, including dietary and exercise behavior modifications. In 2024, the center expanded its services to include the Pride Clinic for the LGBTQ+ community, with a focus on maintaining confidentiality of patient information.

Cosmetic Center offers comprehensive beauty services, including personalized dietary and exercise plans, as well as treatments for skin conditions and various procedures such as Botox, facial and body cosmetic surgery. In 2024, the center expanded its services to include Gastric Sleeve Surgery (Laparoscopic Sleeve Gastrectomy) for weight loss, which has received positive feedback from patients.

GI Center provides diagnosis and treatment for diseases of the digestive system and liver using advanced technologies such as Fibroscan and GI Endoscopy. The center also offers guidance on the prevention and care of digestive health.

Dr. Krittipat Piriyaorncharoenkit, M.D. Presenting the performance of Aikchol 2 Hospital

Trauma Center provides treatment for patients with traffic and industrial accidents through an efficient patient transfer system. The center uses CT Scan and MRI for diagnosis, supported by a team of specialists in emergency care, such as emergency medicine and various surgical fields, to ensure quick and safe treatment for emergency patients.

Social Security the Company serves over 118,795 insured persons from the Social Security Office as of April 15, 2025. The Company provides general medical services to 66.90% of patients through social security benefits, as well as other benefits such as cash, life insurance, Workmen's Compensation, and compensation funds. Additionally, services are provided to 24.68% of patients under government employee benefits.

Ms. Pariyanath Chalermchuang reported the overall accounting and financial performance of the Company for the year 2024. The two hospitals had total revenue of 1,804.38 million baht, a decrease of approximately 24.78 million baht or 1.4% compared to 2023. While revenue from outpatient services increased, revenue from inpatient services declined due to renovations and improvements made to the facilities of both hospitals, which temporarily reduced their capacity to accommodate patients.

The total management costs and expenses for both hospitals amounted to 1,646.59 million baht, an increase of 3.2% from the previous year. Medical treatment costs rose by 4.4%, driven by higher expenses for medicines, medical supplies, and healthcare personnel. Meanwhile, administrative expenses decreased by 3.7% due to adjustments in the allowance for doubtful debts and payments received from government creditors.

EBITDA decreased by 21.8 percent to 241.96 million baht and EBITDA margin decreased from 16.9 percent to 13.4 percent with net profit of 127.01 million baht, decreased by 32.7 percent and earnings per share decreased from 1.26 baht to 0.85 baht.



The main assets that have changed include an increase in cash by 38.02 million baht, a rise in accounts receivable by 3.60 million baht, and a slight decrease in inventory. Meanwhile, net property, plant, and equipment increased by 1.72 million baht due to investments in medical equipment and facility improvements.

The shareholders were given the opportunity to ask questions or express their opinions on this agenda item, but it turned out that no shareholders asked questions or expressed their opinions.

The meeting acknowledged the report of the company's performance and the report of the Board of Directors for the year 2024

Agenda 2 To consider and approve the Financial Statements ended on December 31, 2024

The Chairman assigned Ms. Thitawat Phothanan, Audit Committee Member, to present this agenda.

Ms. Thitawat Phothanan presented a summary of the Company's financial statements for the year ended December 31, 2024. The financial statements had been audited and certified by Ms. Runghapa Saengchan, Certified Auditor No. 10142 from Dhammaniti Auditing Co., Ltd. The auditor expressed an unqualified opinion, stating that the financial statements present fairly, in all material respects, the financial position of the Company in accordance with financial reporting standards.

The Chairman proposed that the Annual General Meeting consider and approve the Company's financial statements for the fiscal year 2024, ending December 31, 2024.

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The Company Secretary assigned by the Chairman proposed the meeting to consider and approve the Financial Statements for the year 2024 ended on December 31, 2024 which required approval from the majority of the shareholders present with voting rights.

Resolution The meeting considered and approved the financial statements for the year 2024 ending on December 31, 2024 with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	76,634,585	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
Total	76,634,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote



Note: In this agenda, there were 4 additional shareholders attending the meeting, totaling 74,488 shares, making a total of 34 shareholders attending the meeting. The total number of shares in this agenda was 76,634,585 shares, representing 51.1206 percent of the total number of shares sold of the Company.

Agenda 3 To consider and approve the allocation of profit and dividend payments for the year 2024

The Chairman informed in the year from January 1, 2024 to December 31, 2024, the Company had a net profit after tax 127,006,763 baht. The Company set aside reserve capital amounting to 10 percent of registered capital as required by law, the Company did not need to allocate a portion of net profit for the period of reserve capital.

Dividend policy: In accordance with the Dividend Payment Policy of the Company, should there be no necessary circumstances, the Board of Directors of the Company shall propose to the shareholders to consider for the distribution of dividends of not less than 50 percent of the net profit after tax.

The Chairman proposed to the meeting to considered and approved the payment of dividends to shareholders from the operating results of the year 2024 in cash at the rate of 0.43 baht per share total amount of 64,460,983.52 baht, equivalent to 50.75 percent of net profit after tax. All dividend payment are subjected to withholding tax at the rate stipulated under the law. On April 28, 2025 the list of eligible shareholders to receive dividend payment will be determined. The dividend is scheduled to be distributed on May 15, 2025.

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The Company Secretary assigned by the Chairman proposed the meeting to consider and approve the allocation of profit and dividend payments for the year 2024. This agenda required approval from the majority of the shareholders present with the right to vote.

Resolution The Meeting consideration voted to approve dividend payment for Financial Year 2024 with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	76,634,585	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
Total	76,634,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote



Agenda 4 To consider and approve the appointment of directors to replace those retiring by rotation.

The Chairman assigned the Company Secretary to act on this agenda.

The company secretary informed in accordance with the Public Limited Companies Act BE 2535 with section 71 of the Public Limited Companies Act BE 2535 (and its amendments) and Article 22 of the Company bylaws, at each Annual General Meeting of Shareholders, one-third of the full number of Directors shall vacate their responsibilities in rotation; if the full number of Directors are not a multiple of three, wherewith the Board of Director total of 8 directors. In 2025, There were 2 Directors retiring by rotation in 2025. Consequently, the number of directors to retire by rotation remains at two (2), as follows:

1. Assoc.Prof.Dr.Sarayut Rueangsuwan, Ph.D. Director, Member of the Nomination and Remuneration Committee
2. Mr. Kudun Sukhumanada Independent, Member of Audit Committee

The Company published on our website an invitation to shareholders to nominate, during September 30, 2024 to December 31, 2024 qualified persons to be elected as Directors in accordance with the Public Limited Companies Act BE 2535, the Securities and Exchange Act BE 2535, the regulations of the Stock Exchange of Thailand, the Securities and Exchange Commission and the Capital Market Supervisory Board, and the rules of corporate governance. However, no such nominations were received

The Board with the exclusion of the Directors with interest in the matter, taking into account the qualifications, expertise and past performances through a process of screening and thorough consideration of the three vacating directors, acknowledged that all three individuals have performed the duties of their responsibilities as Directors with dedication and in accordance with the corporate governance framework, to the benefit of the Company's conduct of business. In view of this, and the fact that they are not involved in any legal disputes, have never been dismissed or otherwise removed from office for a dishonest act in the performance of duties, nor have they been convicted of a criminal offence involving property fraud, as well as the three persons nominated this time have passed through the screening process. or consider carefully The Board of Directors is cautious, excluding directors who are interested parties. The Board recommends that the meeting re-elect the vacating Directors, whose names appear below, for another term as members of the Board:

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The Company Secretary assigned by the Chairman proposed the meeting to consider and approve the appointment of directors to replace those retiring by rotation. In this agenda, shareholders or proxies who have the right to vote are able to vote for the election of directors individually, which must be certified by a majority vote of the shareholders attending the meeting and having the right to vote.

Resolution The meeting considered It was resolved to approve the appointment of the three directors to serve as directors for another term. Thus the votes of the shareholders attending the meeting and having the right to vote as follows:



1. Assoc.Prof.Dr.Sarayut Rueangsuwan, Ph.D.

Vote	Number of Votes	% of Total Votes*
Approve	73,360,205	95.6973
Disapprove	3,298,380	4.3027
Abstain	0	0.0000
Void	0	0.0000
Total	76,658,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

Note : In this agenda, there was 1 additional shareholder attending the meeting, representing 24,000 shares, making a total of 35 shareholders attending the meeting. The total number of shares in this agenda was 76,658,585 shares, representing 51.1367 percent of the total number of shares sold by the Company.

2. Mr. Kudun Sukhumanada

Vote	Number of Votes	% of Total Votes*
Approve	73,360,205	95.6973
Disapprove	3,298,380	4.3027
Abstain	0	0.0000
Void	0	0.0000
Total	76,658,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

Agenda 5 To consider and approve the appointment of new directors and authorized signatories.

The Chairman announced to the meeting that on January 1, 2025, the Board of Directors had resolved to appoint a new Chief Executive Officer (CEO), Dr. Jakapan Bhongsatiern, M.D. After thorough consideration of his qualifications, educational background, professional experience, and expertise, the Board proposed the appointment of Dr. Jakapan Bhongsatiern, M.D. as both Company Director and authorized signatory. Shareholders may review his profile in Enclosure 3, Page 28 of the Meeting Notice.

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The Company Secretary assigned by the Chairman proposed the meeting to consider and approve the appointment of new directors to the position of directors. This agenda must be approved by a majority vote of the shareholders and proxies who attended the meeting and voted.



Resolution The Meeting, considered the matter, resolved to approve the appointment of one new director to serve as a member of the Board of Directors and as an authorized director. The resolution was passed by the votes of the shareholders who attended the meeting and were eligible to vote, as follows:

Mr. Jakapan Bhongsatiern

Vote	Number of Votes	% of Total Votes*
Approve	76,658,585	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
Total	76,658,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

Agenda 6 To consider and approve the Directors' remuneration.

The Chairman proposed to the meeting considers and approved the remuneration of the Board of Directors, sub-committees consist of the Audit Committee, Nomination and Remuneration Committee, and Board of Directors. Which is reasonable to the current situation as follow;

1. The remuneration of the directors	2025 (Proposed Year)	2024
1.1 Meeting allowance		
1.1.1 Chairman	15,000 Baht / Meeting	15,000 Baht / Meeting
1.1.2 Each Director	12,000 Baht / Meeting	12,000 Baht / Meeting
1.2 Monthly Compensation		
1.2.1 Chairman	30,000 Baht / Meeting	30,000 Baht / Meeting
1.2.2 Each Director	20,000 Baht / Meeting	20,000 Baht / Meeting
1. The remuneration of the directors	2025 (Proposed Year)	2024
1.3 Remuneration*	Totaling 7.2 Million Baht	Totaling 7.2 Million Baht
1.4 Other benefits	Medical expenses not more than 500,000 Baht / person	Medical expenses not more than 500,000 Baht / person
2. Sub-Committee	2025 (Proposed Year)	2024
2.1 The Audit Committee		
2.1.1 Meeting allowance		
2.1.1.1 Chairman	12,000 Baht / Meeting	12,000 Baht / Meeting
2.1.1.2 Each Director	10,000 Baht / Meeting	10,000 Baht / Meeting



2. Sub-Committee		2025 (Proposed Year)	2024
2.1.2	Monthly Compensation		
2.1.2.1	Chairman	-None-	-None-
2.1.2.2	Each Director	-None-	-None-
2.1.3	Other benefit	-None-	-None-
2.2	The Nomination and Remuneration Committee		
2.2.1	Meeting allowance		
2.2.1.1	Chairman	12,000 Baht / Meeting	12,000 Baht / Meeting
2.2.1.2	Each Director	10,000 Baht / Meeting	10,000 Baht / Meeting
2.2.2	Monthly Compensation		
2.2.2.1	Chairman	-None-	-None-
2.2.2.2	Each Director	-None-	-None-
2.2.3	Other benefit	-None-	-None-
2.3	The Executive Committee		-None-
2.3.1	Meeting allowance	-None-	-None-
2.3.1.1	Chairman	-None-	-None-
2.3.1.2	Each Director	-None-	-None-
2.3.2	Remuneration	-None-	-None-
2.3.3	Other benefit	-None-	-None-

Remark: *The Board of Directors shall allocate their remuneration among themselves.

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The company secretary was assigned as the Chairman proposed that the Meeting vote on the remuneration of the directors and sub-committee, which required approval from at least two-thirds of shareholders present with the right to vote.

Resolution The meeting considered resolved to approve the directors' remuneration with the following votes:

Vote	Number of Votes	% of Total Votes*
Approve	76,658,585	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
Total	76,658,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote



Agenda 7 To consider and approve the appointment of the Company's auditors and their remuneration for the year 2024.

The Chairman announced to the meeting that, pursuant to Article 41 of the Company's Articles of Association, the Annual General Meeting is required to annually consider the appointment of an auditor and the approval of audit fees. The Audit Committee has completed its selection process for the Company's 2025 auditor and determined the proposed audit fees. Following the Committee's recommendation, the Board of Directors resolved to propose to the shareholders the appointment of Dharmniti Auditing Co., Ltd. as the Company's auditor for 2025, given the firm's established reputation. The proposed audit fee for 2025 is 1,000,000 Baht (One Million Baht)

The Board of Directors, in agreement with the Audit Committee's recommendations proposed that the Meeting appointed as auditor for the year 2025 the following certified public accountant from Dharmniti Audit Co., Ltd. :

1. Ms. Potjanarat Siripipat License number 9012 or
2. Mr. Thanawut Piboonsawat License number 6699 or
3. Ms. Techinee Pompenpob License number 10769 or

4. Other auditors approved by the Securities and Exchange Commission, which Dharmniti Auditing Company Limited has assigned to be responsible auditors

Each of the proposed auditors has no relationship with, no conflict of interest in, and is not related to the Company, its management, or major shareholders. The Meeting is proposed to approve the auditor's remuneration for the year 2025 in the amount of Baht 1,000,000 (One Million Baht), which is Baht 35,000 higher than that of the year 2024. The details are as follows:

1. Review quarterly financial statements	
170,000 baht per quarter x 3 quarters	510,000.- Baht
2. Review of the 2025 annual financial statements, including the control assessment	
General interior of computer systems for accounting processing	
General Control and check the inventory twice a year	<u>490,000.-</u> Baht
Total	<u>1,000,000.-</u> Baht

There is an opportunity for shareholders to ask questions or express opinions on this agenda. It appears that no one asked or expressed any opinion.

The company secretary was assigned as the Chairman proposed consider and approve the appointment of the Company's auditors and their remuneration for the year 2025. This agenda required approval from the majority of the shareholders present with the right to vote.

Resolution The meeting considered and resolved to approve the appointment of auditors and determine the auditors' remuneration for the year 2025.



Vote	Number of Votes	% of Total Votes*
Approve	76,658,585	100.0000
Disapprove	0	0.0000
Abstain	0	0.0000
Void	0	0.0000
Total	76,658,585	100.0000

*Percentage of total votes of shareholders and proxies who attended the meeting and had the right to vote

Agenda 8 Other matters (if any)

-None-

The Chairman stated to the meeting that the Company had opened opportunities for shareholders to propose agenda items by announcing the criteria and procedures for proposing agenda items from September 30, 2024 to December 31, 2024 via the Company's website. As a result, no shareholders proposed any agenda items to the Company. Therefore, there were no other matters for consideration in this agenda item.

At the end of the Annual General Meeting, shareholders raised additional questions, and the Company Secretary read out the suggestions submitted by shareholders via electronic mail. The details of the questions, answers, and suggestions have been documented and attached as an appendix to the minutes of the meeting.

The Chairman thanked all shareholders for attending the meeting and for their continued support of the Company, and closed the meeting.

The meeting closed at 11:00 AM.

Sign.....Mr. Apirag Vanich.....The Chairperson of the Meeting
(Mr. Apirag Vanich)

Sign.....Mrs. Wilailux Srisuwan.....Company Secretary
(Mrs. Wilailux Srisuwan)

Meeting Minutes



Attachments

Questions - Answers

Annual General Meeting of Shareholders 2025 (47th)

Aikchol Hospital Public Company Limited

Mr. Kanti Udomsangthatham Shareholder

- Question**
1. Could the company elaborate on the key strategic initiatives planned by the new executive management team?
 2. What will be the operational and financial impact of the co-payment scheme on hospital operations?
 3. There is it predicted that this year social security payments will decrease adj.RW > 2 as in previous years?

Mr. Jakapan Bhongsatiren Chief Executive Officer (CEO)

- Answer**
1. In 2025, our key objectives will be service quality improvement across all branches and stringent cost management to enhance customer retention.
 2. Regarding co-payment for medical services, the executive team views that this measure is unlikely to negatively impact the hospital's revenue. Rather, it presents an opportunity to develop innovative marketing approaches for the hospital.
 3. It is expected to decrease as in previous years. However, Aikchol 2 Hospital has adjusted its reimbursement process to be faster in order to minimize the impact of the reduced compensation adj. RW>2

The company secretary read the questions that were submitted through electronic mail

Mr. Kraisaak Yongkulwanit shareholder proposed the following suggestion:

1. Why has the 2025 shareholders' meeting not been arranged to include an online participation option alongside the in-person meeting? The costs associated with hosting the meeting online are likely to be minimal.
2. It is requested that the breakdown of revenue from the Social Security Office (SSO) and the National Health Security Office (NHSO) versus revenue from life insurance companies and cash-paying customers be included in the management's explanation and analysis published quarterly and in the annual report. According to the 2024 annual report, the outstanding medical service receivables from the Social Security Office and the National Health Security Office total 99,572,866 THB, while the total revenue amounts to 1,804,378,678 THB. This represents 5.52% of revenue as outstanding, which introduces a level of uncertainty. In some years, a provision for credit loss of 24% of these outstanding receivables must be set aside, which impacts the profit reported each year or quarter.

The meeting took note of the suggestion.

.....